Overview

Intravitreal Bevacizumab for Retinal Disorders

Status:
Unknown status
Trial end date:
2006-11-01
Target enrollment:
0
Participant gender:
All
Summary
Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Narayana Nethralaya
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM
following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis
which is FDA approved.

- Myopic CNVM, Idiopathic CNVM, Inflammatory CNVM and other conditions associated with
CNVM.

- Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant
macular oedema (CSME) etc. that affects vision and does not respond adequately to
usual treatment methods.

- Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.

Exclusion Criteria:

- Patients with poor compliance

- Patients with uncontrolled diabetes and hypertension or any other medical condition
that increase the risk of complications like recent history of Stroke or myocardial
infraction (< one year). (Physician clearance was obtained for all patients).

- Patients who had undergone major surgery 28 days before, were excluded from the study
and it was also suspended prior to elective surgery.